English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB)
Condensed financial report (PDF 0.5 MB)
Download the podcast (MP3 30 MB)
Download the presentation (PDF 4.7 MB)
Novartis Q4 2024 impact and sustainability update (PDF 1.0 MB)
This report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create sustainable value for diverse stakeholders. It follows requirements of the Swiss Code of Obligations and various voluntary reporting frameworks and standards.
These reports provide a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices. They are filed with the SIX Swiss Exchange in Switzerland and the Securities and Exchange Commission in the US.
Annual Report 2024 (PDF 3.5 MB) | Form 20-F 2024 (PDF 3.4 MB)
| Key figures1 | Continuing operations2 | ||
|---|---|---|---|
| FY 2024 (USD m) | FY 2023 (USD m) | % change (USD/cc) | |
| Net sales | 50,317 | 45,440 | 11 (cc: 12) |
| Operating income | 14,544 | 9,769 | 49 (cc: 55) |
| Net income | 11,939 | 8,572 | 39 (cc: 45) |
| EPS (USD) | 5.92 | 4.13 | 43 (cc: 49) |
| Free cash flow | 16,253 | 13,160 | 24 |
Core | |||
| Operating income | 19,494 | 16,372 | 19 (cc: 22) |
| Net income | 15,755 | 13,446 | 17 (cc: 21) |
| EPS (USD) | 7.81 | 6.47 | 21 (cc: 24) |
English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB)
Condensed financial report (PDF 0.5 MB)
Download the podcast (MP3 30 MB)
Download the presentation (PDF 4.7 MB)
Novartis Q4 2024 impact and sustainability update (PDF 1.0 MB)
| Key figures1 | Continuing operations2 | ||
|---|---|---|---|
| FY 2023 (USD m) | FY 2022 (USD m) | % change (USD/cc) | |
| Net sales | 45,440 | 42,206 | 8 (cc: 10) |
| Operating income | 9,769 | 7,946 | 23 (cc: 39) |
| Net income | 8,572 | 6,049 | 42 (cc: 62) |
| EPS (USD) | 4.13 | 2.77 | 49 (cc: 70) |
| Free cash flow | 13,160 | 12,123 | 9 |
Core | |||
| Operating income | 16,372 | 14,794 | 11 (cc: 18) |
| Net income | 13,446 | 11,946 | 13 (cc: 19) |
| EPS (USD) | 6.47 | 5.48 | 18 (cc: 25) |
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)
Condensed financial report (PDF 0.6 MB)
Download the podcast (MP3 34 MB)
Download the presentation (PDF 5.5 MB)
Novartis Q4 2023 Impact and Sustainability Update (PDF 0.6 MB)
| Key figures1 | FY 2022 (USD m) | FY 2021 (USD m) | % change (USD/cc) |
|---|---|---|---|
| Net sales | 50,545 | 51,626 | -2 (cc: 4) |
| Operating income | 9,197 | 11,689 | -21 (cc: -13) |
| Net income | 6,955 | 24,018 | -71 (cc: -67) |
| EPS (USD) | 3.19 | 10.71 | -70 (cc: -66) |
| Free cash flow | 11,945 | 13,282 | -10 |
Core | |||
| Operating income | 16,665 | 16,588 | 0 (cc: 8) |
| Net income | 13,352 | 14,094 | -5 (cc: 3) |
| EPS (USD) | 6.12 | 6.29 | -3 (cc: 6) |
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)
Condensed financial report (PDF 0.5 MB)
Download the presentation (PDF 5.1 MB)
Download the podcast (MP3 45 MB)
| Key figures1 | FY 2021 (USD m) | FY 2020 (USD m) | % change (USD/cc) |
|---|---|---|---|
| Net sales | 51,626 | 48,659 | 6 (cc: 4) |
| Operating income | 11,689 | 10,152 | 15 (cc: 13) |
| Net income | 24,018 | 8,071 | 198 (cc: 195) |
| EPS (USD) | 10.71 | 3.55 | 202 (cc: 200) |
| Free cash flow | 13,282 | 11,691 | 14 |
Core | |||
| Operating income | 16,588 | 15,416 | 8 (cc: 6) |
| Net income | 14,094 | 13,158 | 7 (cc: 5) |
| EPS (USD) | 6.29 | 5.78 | 9 (cc: 7) |
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)
| Key figures2 | Continuing operations1 | ||
|---|---|---|---|
| FY 2020 (USD m) | FY 2019 (USD m) | % change (USD/cc) | |
| Net sales | 48,659 | 47,445 | 3 (cc: 3) |
| Operating income | 10,152 | 9,086 | 12 (cc: 19) |
| Net income | 8,071 | 7,147 | 13 (cc: 20) |
| EPS (USD) | 3.55 | 3.12 | 14 (cc: 21) |
| Free cash flow | 11,691 | 12,937 | -10 |
Core | |||
| Operating income | 15,416 | 14,112 | 9 (cc: 13) |
| Net income | 13,158 | 12,104 | 9 (cc: 12) |
| EPS (USD) | 5.78 | 5.28 | 9 (cc: 13) |
English (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)
Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.